Hormone replacement therapy in women with cancer and risk of cancer-specific mortality and cardiovascular disease : A protocol for a cohort study from Scotland and Wales.

Funding This work was supported by Cancer Research UK (reference C37316/A29656). The funder had no role in study design, data collection, data analysis, data interpretation or writing the manuscript.Peer reviewedPublisher PD

Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies

Acknowledgements Access to UK Biobank data was approved and facilitated by UK Biobank (application number: 34374). Access to Primary Care Clinical Informatics Unit (PCCIU) data was approved and facilitated by the PCCIU Research team, University of Aberdeen. Access to the UK Biobank was funded by a Cancer Research UK Population Research Postdoctoral Fellowship awarded to ÚCMcM. Funding: Access to the UK Biobank was funded by a Cancer Research UK Population Research Postdoctoral Fellowship awarded to ÚCMcM. Liu P was supported by a joint scholarship from Queen's University Belfast and the Chinese Scholarship Council (201708060458). Data availability: The UK Biobank data (https://www.ukbiobank.ac.uk/) and PCCIU data (https://www.abdn.ac.uk/iahs/research/primary-care/pcciur/) are available, following the access procedures, for researchers to access to conduct health related research in the public interest.Peer reviewedPostprin

Statin use and risk of liver cancer : Evidence from two population-based studies

The analysis of UK Biobank has been conducted using the UK Biobank Resource under Application Number 34374. We acknowledge collaboration with the Research Applications and Data Management Team lead by Ms Katie Wilde, University of Aberdeen in conducting our study. KTT is supported by the Vietnam International Education Cooperation Department. Access to PCCIU data was provided by Queen's University Belfast and the Centre for Academic Primary Care, University of Aberdeen. Access to the UK Biobank was funded by a Cancer Research UK Population Research Postdoctoral Fellowship awarded to ÚCMcM.Peer reviewedPostprin

Hormone replacement therapy and cancer mortality in women with site specific cancers : A cohort study using linked medical records.

Acknowledgements We would like to acknowledge the support of the eDRIS team (Public Health Scotland) for their involvement in obtaining approvals, provisioning and linking data and the secure analytical platform within the National Safe Haven. We would also like to acknowledge support of SAIL Databank for facilitating access to the dataset from Wales. We acknowledge the contribution of EMIS practices who contribute to the QResearch database and the Chancellor, Masters and Scholars of the University of Oxford for continuing to develop and support the QResearch database. The Hospital Episode Statistics data used in the English portion of this analysis are re438 used by permission from NHS Digital who retain the copyright. We thank the Office for National Statistics (ONS) for providing the mortality data for the English analyses. The ONS bears no responsibility for the analysis or interpretation of the data. The authors would also like to thank the PPI representatives for providing a patient and public perspective on the study design, findings, interpretation of the study and lay summary materials.Peer reviewe

Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies

The analysis of UK Biobank has been conducted using the UK Biobank Resource under Application Number 34374. We acknowledge collaboration with the Research Applications and Data Management Team lead by Ms Katie Wilde, University of Aberdeen in conducting this study. KTT is supported by the Vietnam International Education Cooperation Department. Access to PCCIU data was provided by Queen’s University Belfast and the Centre for Academic Primary Care, University of Aberdeen. Access to the UK Biobank was funded by a Cancer Research UK Population Research Postdoctoral Fellowship awarded to ÚCMcM. HGC is a co-investigator of the UKCRC Centre of Excellence for Public Health Northern Ireland.Peer reviewedPostprin

Medications that relax the lower oesophageal sphincter and risk of oesophageal cancer : An analysis of two independent population-based databases

Acknowledgements We acknowledge collaboration with the Research Applications and Data Management Team lead by Ms Katie Wilde, University of Aberdeen in conducting our study. This research has been conducted using the UK Bio-bank Resource under application number 34374.Peer reviewedPostprin

Cancer-specific mortality in breast cancer patients with hypothyroidism: a UK population-based study

PURPOSE: Epidemiological studies have indicated a higher prevalence of hypothyroidism in breast cancer patients, possibly related to shared risk factors and breast cancer treatments. However, few studies have evaluated how hypothyroidism impacts survival outcomes in breast cancer patients. We aimed to determine the association between hypothyroidism and breast cancer-specific and all-cause mortality. METHODS: We conducted a population-based study using the Scottish Cancer Registry to identify women diagnosed with breast cancer between 2010 and 2017. A matched comparison cohort of breast cancer-free women was also identified. Using hospital diagnoses and dispensed prescriptions for levothyroxine, we identified hypothyroidism diagnosed before and after breast cancer diagnosis and determined associations with breast cancer-specific and all-cause mortality. Cox proportional hazards regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CI) adjusted for potential confounders. RESULTS: A total of 33,500 breast cancer patients were identified, of which 3,802 had hypothyroidism before breast cancer diagnosis and 565 patients went on to develop hypothyroidism after. Breast cancer patients had higher rates of hypothyroidism compared with cancer-free controls (HR 1.14, 95% CI 1.01–1.30). Among breast cancer patients, we found no association between hypothyroidism (diagnosed before or after) and cancer-specific mortality (before: HR 0.99, 95% CI 0.88–1.12, after: HR 0.97, 95% CI 0.63–1.49). Similar associations were seen for all-cause mortality. CONCLUSION: In a large contemporary breast cancer cohort, there was little evidence that hypothyroidism, either at diagnosis or diagnosed after breast cancer, was associated with cancer-specific or all-cause mortality. SUPPLEMENTARY INFORMATION: The online version of this article contains supplementary material available 10.1007/s10549-022-06674-5